Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | APEX1 | P27695 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.47 |
| ▸ | RELA | Q04206 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12768344 | 0.97 | HTT (0.57) | HTTPOLBAPEX1TDP1NPC1 | |
| SCHEMBL12768348 | 0.96 | HTT (0.56) | HTTPOLBAPEX1TDP1NPC1 | |
| SCHEMBL13574932 | 0.96 | HTT (0.60) | HTTPOLBAPEX1TDP1NPC1 | |
| SCHEMBL15224973 | 0.96 | HTT (0.60) | HTTPOLBAPEX1TDP1NPC1 | |
| SCHEMBL1532040 | 0.95 | HTT (0.55) | HTTPOLBAPEX1TDP1NPC1 | |
| SCHEMBL13574931 | 0.95 | HTT (0.56) | HTTPOLBAPEX1TDP1NPC1 | |
| SCHEMBL12768332 | 0.94 | POLB (0.58) | HTTPOLBAPEX1TDP1NPC1 | |
| SCHEMBL15478755 | 0.93 | HTT (0.62) | HTTPOLBAPEX1TDP1NPC1 | |
| SCHEMBL14346662 | 0.93 | POLB (0.64) | HTTPOLBAPEX1TDP1NPC1 | |
| SCHEMBL8667962 | 0.92 | POLB (0.70) | HTTPOLBAPEX1TDP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2698413-B1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2016-12-28 | — | — | EP | claimed |
| EP-2698413-A2 | Mesogen containing compounds | TRANSITIONS OPTICAL, INC. (US) | 2014-02-19 | — | — | EP | claimed |
| US-7910019-B2 | Mesogen containing compounds | TRANSITIONS OPTICAL, INC. (US) | 2011-03-22 | — | — | US | claimed |
| US-20090326186-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-31 | — | — | US | claimed |
| US-20090323011-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-31 | — | — | US | claimed |
| US-20090323012-A1 | LIQUID CRYSTAL COMPOSITIONS COMPRISING MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPITCAL, INC. (US) | 2009-12-31 | — | — | US | claimed |
| EP-2698413-B1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2016-12-28 | — | — | EP | disclosed |
| EP-2698413-A2 | Mesogen containing compounds | TRANSITIONS OPTICAL, INC. (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2698411-A2 | Mesogen containing compounds | TRANSITIONS OPTICAL, INC. (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2698411-A2 | Mesogen containing compounds | TRANSITIONS OPTICAL, INC. (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2303988-B9 | LIQUID CRYSTAL COMPOSITIONS COMPRISING MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-2303988-B1 | LIQUID CRYSTAL COMPOSITIONS COMPRISING MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2303987-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2011-04-06 | — | — | EP | disclosed |
| US-7910019-B2 | Mesogen containing compounds | TRANSITIONS OPTICAL, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090326186-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090323011-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009158483-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326186-A1 | MESOGEN CONTAINING COMPOUNDS | MYOC, BMP2, RARG | HTT 1202/4885POLB 297/4885APEX1 2951/4885 |
| US-20090323011-A1 | MESOGEN CONTAINING COMPOUNDS | MYOC, BMP2, RARG | HTT 1202/4885POLB 297/4885APEX1 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.